Introduction
Influenza is a major cause of morbidity in people of all ages. The primary strategy for the prevention of influenza is vaccination. Inactivated influenza vaccines have been recommended since the 1960s for the elderly and those with underlying medical conditions. In 2004, the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices recommended vaccination against influenza for all children aged 6-23 months [1] ; in 2008, this recommendation was expanded to include all children and adolescents through 18 years of age [2] .
In the United States, intranasal live attenuated influenza vaccine (LAIV) and injectable trivalent inactivated influenza vaccine (TIV) are approved for use in eligible children and adolescents. Some TIV formulations are approved for use in eligible children 6 months and older. The Ann Arbor strain LAIV (MedImmune, LLC, Gaithersburg, MD) was licensed in 2003 for use in eligible individuals aged 5-49 years. Initially, LAIV was not approved for use in children younger than 5 years because an increased rate of asthma and wheezing events was noted in young children in one study [3] . A subsequent study that was prospectively designed to evaluate wheezing showed an increased rate of medically attended wheezing in LAIV-vaccinated children aged <24 months, with no increase in LAIV-vaccinated children ≥24 months of age [4, 5] . Based on this study, in 2007 the US Food and Drug Administration expanded its approval of LAIV to include children aged 24-59 months [6] . From the initial approval of LAIV through the 2011-2012 season, more than 50 million doses have been distributed for use in the United States, with use predominantly occurring among children, military personnel, and healthcare workers.
During prelicensure clinical trials, the safety of LAIV was evaluated in 26,031 children aged 2-18 years, including data from 14 placebo-controlled studies (N = 10,693), 6 TIV-controlled studies (N = 4245) and 1 community-based open-label study (N = 11,096) [7, 8] . Previous comparative studies of LAIV and TIV have generally demonstrated comparable safety of the 2 vaccines among individuals ≥2 years of age, with most adverse reactions from either vaccine being mild, transient, and of minimal clinical significance [7] . At the time of the initial approval of LAIV in the United States, Med-Immune committed to the US Food and Drug Administration to conduct a postmarketing evaluation of the safety of LAIV in 60,000 LAIV recipients 5-49 years of age, with 20,000 individuals each aged 5-8 years, 9-17 years, and 18-49 years. The intent of this postmarketing study was to conduct a broad assessment of safety, evaluating all events and specific prespecified events. The current analysis describes the results among children 5-8 years and 9-17 years of age; results for adults 18-49 years of age will be reported separately.
Methods

Study design
Kaiser Permanente (KP) health plan is a large integrated health maintenance organization with medical centers in multiple areas of the United States. The KP database was previously used to evaluate the safety of LAIV in a randomized, placebo-controlled study [3] . The current study was a prospective observational study and collected data from the Northern California, Hawaii, and Colorado KP sites, where inclusive membership totals approximately 4 million individuals. All medical care for members is provided through the health plan, and clinic visits and treatments are documented in comprehensive databases. Influenza vaccines are provided to all members at no cost, and extensive programs are in place to ensure rapid and convenient distribution of vaccines to members each year.
Commercially available LAIV was supplied each year by Med-Immune, and commercially available TIV was purchased by KP as part of routine practice. Each annual formulation of the vaccines contained the strains recommended for inclusion by the US Public Health Service. Subjects were screened for underlying medical conditions and provided the appropriate vaccine based on the eligibility criteria in each vaccine's package insert, physician discretion, and patient choice. The protocol was reviewed and approved by the KP Institutional Review Board.
The study's objective was to assess the safety of LAIV, by comparing the rates of medically attended events (MAEs) in LAIV recipients, including all MAEs by diagnosis and specifically serious adverse events (SAEs), anaphylaxis, urticaria, asthma, wheezing, prespecified diagnoses of interest, and rare events potentially related to wild-type influenza, to the rates in 3 nonrandomized control groups.
Study populations
Through KP immunization registries, approximately 40,000 individuals 5-17 years of age who were immunized with LAIV as part of routine clinical practice were identified from the 2003-2004 through the 2007-2008 influenza seasons. The population included approximately 20,000 individuals in each of 2 age groups; 5-8 years and 9-17 years. Subjects from 5 to 8 years of age may have received 1 or 2 doses of LAIV in accordance with influenza vaccination recommendations whereas subjects ≥9 years of age were expected to receive only 1 dose. Study subjects with high-risk underlying medical conditions such as cancer, organ transplantation, diabetes, endocrine and metabolic disorders, blood disorders, liver disorders, kidney disorders and cardiopulmonary disorders (for whom LAIV was not recommended) were identified via automated extraction of healthcare databases and were excluded from analysis in all cohorts.
Three nonrandomized control groups were identified for comparison: a within-cohort (i.e., self-control) control, matched concurrent unvaccinated controls, and matched concurrent TIV recipient controls. For the within-cohort analysis, LAIV recipients served as their own controls based on the observation time after vaccination. Risk intervals of 3 and 21 days postvaccination were compared with control intervals from 4 to 42 days postvaccination (for the 3-day risk interval) and 22 to 42 days postvaccination (for a 0-to 21-day risk interval). Unvaccinated controls were selected from the pool of individuals who were members of KP during the same month that the reference LAIV recipient was vaccinated and included those who did not receive TIV or LAIV. For the unvaccinated population, the effective vaccination date was the date on which the matched LAIV recipient was vaccinated. TIV-vaccinated controls were selected from the pool of individuals who received TIV but not LAIV during the same month that the reference LAIV recipient was vaccinated. Other matching factors included region (Northern California, Colorado, Hawaii), age (within 1 year), sex, prior year healthcare use (number of hospital, emergency department [ED], and clinic visits), and specific medical center (only for subjects from Northern California, where there were 48 clinics). Dose number (first or second dose in those 5-8 years of age) was also matched between LAIV recipients and TIV controls for subjects from Northern California and Hawaii; matching by dose was not possible in Colorado owing to the small number of subjects. Unvaccinated and TIV-vaccinated concurrent controls were matched 1:1 with LAIV recipients, respectively. If a match could not be found within a specific control group, the LAIV recipient was excluded from the cohort comparison. Study day 0 for each participant in the LAIV-vaccinated group was the date of receipt of the first dose of the current seasonal LAIV formulation. Study day 0 for each unvaccinated and TIV-vaccinated matched concurrent control was defined as the date of vaccination of the reference LAIV recipient or the date of the first dose of current TIV, respectively. Subsequent study days were numbered sequentially thereafter.
Outcome measures
Diagnoses from all MAEs occurring in study subjects were collected from outpatient clinic visits, ED visits, and hospital admissions via extraction of records from the KP utilization databases. An MAE was defined as a coded medical diagnosis made by a healthcare provider and associated with a medical encounter. One or more MAEs could be assigned for a single encounter. MAEs were evaluated regardless of whether the individual had a pre-existing history of the same or a similar condition; the analysis was not restricted to incident MAEs.
Consistent with a prior study of LAIV safety conducted in KP [3] , medical events that were hypothesized a priori as potentially causally related to vaccination based on the pathophysiology of wild-type influenza were grouped together in 5 event categories and analyzed cumulatively across all settings as prespecified diagnoses of interest (PSDI), which included (1) acute respiratory tract events (ART), (2) acute gastrointestinal tract events (AGI), (3) asthma and wheezing events (AW), (4) systemic bacterial infections (SBI), and (5) rare diagnoses potentially related to wildtype influenza (WTI). Asthma and wheezing events were a subset of ART; AW events were followed for 180 days, in contrast to the 42 days surveillance for other PSDIs. These event categories are detailed in Supplemental Digital Content 1, a table of descriptions of the prespecified diagnoses of interest. PSDI events were analyzed individually and cumulatively by category. Individual chart reviews were performed for select outcomes of interest to confirm specific diagnoses. SAEs were defined in a similar manner to previous LAIV studies, were identified from 0 to 42 days postvaccination, and were reported regardless of the investigator's assessment of the relationship to LAIV. Any subsequent serious event that was considered to be related to LAIV was also reported as an SAE [4] . Assessment of the relationship between an SAE and LAIV was conducted by KP staff and based upon the temporal relationship of the event to the administration of the vaccine, whether an alternative etiology could be identified, and biological plausibility. Pregnancies were identified by obtaining any pregnancy related MAE within 42 days of vaccination in any setting or any pregnancy related MAE in the ED or hospital setting within 180 days of vaccination. Chart review was performed on any subject with a pregnancy related visit to verify the pregnancy and obtain outcome information. Information on deaths in Northern California was obtained from KP databases, the State of California death certificate files, and the Social Security Administration Death Master File of all known vaccinees from the start of the study. These databases were cross-referenced with the subject's medical record.
For each incidence rate comparison between LAIV recipients and a control group, a rate ratio was calculated. Rate comparisons of individual MAEs were made for each setting separately; for PSDI, comparisons were made for all settings combined. For MAEs occurring in the hospital setting, any duration of inpatient hospitalization was counted, unlike the ≥24-h requirement for an SAE. For each control group, rate comparisons were made for each period (3, 21, 42, or 180 days or entire study period), age group (5-8, 9-17 years), setting (clinic, hospital, ED), and dose number for ages 5 to 8 years as outlined in Table 1 .
Asthma and wheezing events were of particular interest in this study and were captured in multiple ways. A specific asthma and wheezing analysis was conducted as part of the PSDI analysis through 180 days. The term "asthma/reactive airway disease (RAD)" used in this analysis encompassed the individual diagnoses of asthma, cough variant asthma, and exercise-induced asthma, and the term "wheezing/shortness of breath (SOB)" included the diagnoses of wheezing and dyspnea/SOB. Asthma and wheezing events were also captured as part of the PSDI analysis of acute respiratory tract events in the 21-and 42-day periods. Lastly, individual diagnoses of asthma and wheezing events were analyzed as individual MAEs in each of 3 settings: clinic, ED, and hospital.
Statistical analyses
Event rates were calculated per 1000 person-months. Relative risks (RR) were calculated as the ratio of the incidence rates of the two comparison groups without adjustment for any covariate. Hazard ratios (HR) were also calculated adjusting for matching factors and seasonal changes in background rates. Adjusted hazard ratios were obtained from the Cox proportional hazards model implementing the counting-process style of input [9] . This style of input facilitated the use of time-dependent covariates and of calendar time as the time structure of the model, which controlled for any seasonal effects. Analyses modelled the first incidence of each event or class of event (e.g., respiratory events) as the response variable. The RR for the main effect (or a covariate) was estimated by eˇwhere ˇ is the regression coefficient for the specific effect or covariate of interest. The ninety five percent confidence intervals for the RR were calculated using a normal approximation, with the variance derived from the appropriate diagonal element of the estimated covariance matrix.
In a conservative approach, statistical significance was declared if either the exact method or the Cox model showed statistical significance. A statistically significant increased risk associated with LAIV vaccination was declared if the lower bound of the exact 95%CI or the CI constructed from the Cox proportional model was >1.00. Likewise, a statistically significant decreased risk associated with LAIV vaccination was declared if the upper bound of either 95%CI was <1.00. Statistical significance was determined before rounding. The corresponding P values were also provided. When the control group had a zero event, the RR or HR was not estimable owing to a zero value of the denominator. If the P value was available, statistical significance was declared according to the P value at the significance level of 0.05.
According to the prespecified data analysis plan, CIs were constructed without multiplicity adjustment. To facilitate interpretation of the results, a post hoc analysis was conducted using the Bonferroni method and statistical significance was declared at the adjusted significance level of 0.000002. The sample size of 20,000 per age group provided ≥90% power within each age group to observe a statistically significant increased RR if the true RR was ≥2.0 for events that occurred at a rate of 1 in 500 or if the true RR was ≥2.5 for events that occurred at a rate of 1 in 1000. For events that occurred at rates of 1 in 100 or 1 in 50, the study provided ≥90% power to observe a statistically significant increased RR if the true RR was ≥1.4 or ≥1.25, respectively, in each age cohort. All analyses were performed using SAS ® statistical software, version 8.2 (SAS Institute, Inc., Cary, NC, USA).
Results
A total of 43,702 unique subjects 5-17 years of age were vaccinated with 53,369 doses of Ann Arbor strain LAIV during the 5 Table 2 .
Deaths and serious adverse events
A total of 3 deaths from all causes within 180 days of LAIV vaccination were observed during the entire study period. Deaths included a 17-year-old who died in an automobile accident, a 13year-old who died from asphyxiation after choking on food, and an 11-year-old who died in a house fire. All were considered by the investigator to be unrelated to LAIV. During the same time period, 1 death occurred in each of the unvaccinated and TIV-vaccinated control groups. The rate of death was not significantly higher in those vaccinated with LAIV compared with those unvaccinated or vaccinated with TIV.
There were 68 SAEs (3 in the clinic setting, 1 in the ED setting and 64 in the hospital setting) in 64 subjects within 42 days of vaccination with LAIV. SAEs within 42 days of vaccination occurred at an incidence rate of 0.56 and 0.47 per 1000 person-months after the first and second dose, respectively, in those 5-8 years of age and at 1.08 per 1000 person-months in those 9-17 years of age. Of those occurring in 5-to 8-year-olds (n = 19) the most common primary diagnoses were trauma (n = 4), appendicitis (n = 2) and gastroenteritis (n = 2). Of those occurring in 9-to 17-year-olds (n = 49) the most common primary diagnoses were psychiatric (n = 17), appendicitis (n = 6), and trauma (n = 5). In the analysis, the incidence rates of SAEs overall and by specific diagnosis were not significantly higher or lower in LAIV recipients relative to control groups in any comparison.
Of the SAEs occurring within 42 days postvaccination, only 2 events were categorized by investigators as possibly related to LAIV. A 9-year-old male subject experienced dystonic tongue posturing 3 days postvaccination that was classified as a nonspecific paroxysmal spell. The subject's past medical history was significant for a previous episode of prolonged dystonic tongue posturing following a febrile seizure. The subject recovered in full. A case of Bell's palsy occurred in a 10-year-old male subject 2 days postvaccination. The subject's past medical history was significant for a visit to the ED for left-sided headache, left-sided facial numbness, and nasal congestion 2 days before receiving LAIV. The subject recovered in full. In all children 9-17 years of age, Bell's palsy occurred in 2, 7, and 0 children vaccinated with LAIV or TIV or unvaccinated, respectively.
Hospitalizations
There were 477 hospitalizations that were observed within 180 days of LAIV vaccination. Among those 5-8 years of age (n = 169) the most common first diagnoses were trauma (n = 31), otitis media (n = 17), and tonsillitis (n = 15). Most hospitalizations for otitis media (94%) were for prescheduled tympanostomy tube placements. Among those 9-17 years of age (n = 308), the most common first diagnoses were psychiatric (n = 68), trauma (n = 59) and appendicitis (n = 28). The only diagnoses significantly increased in LAIV recipients relative to control groups were tonsillitis within 42 days in those 9-17 years of age (LAIV, n = 7; unvaccinated, n = 1) and trauma within 42 days in those 5-8 (LAIV, n = 8; unvaccinated, n = 1) and 9-17 (LAIV, n = 13; TIV, n = 4) years of age. All hospitalizations for tonsillitis were for prescheduled tonsillectomies. One diagnosis in the hospital setting was significantly decreased in LAIV recipients relative to control groups: pregnancy/delivery within 42 days in 9-to 17-year-olds (LAIV, n = 0; TIV, n = 9).
There were 12 hospitalizations in 10 subjects due to rare diagnoses potentially related to wild-type influenza from vaccination to the end of the study period (end of surveillance for the final study subject); 1 subject was hospitalized 3 times for viral encephalitis. The only rare diagnosis event present in more than 1 subject was viral meningitis (n = 5). One death due to viral myocarditis occurred 1586 days postvaccination. No event was considered by investigators to be causally related to LAIV. In the analysis, no rare diagnosis potentially related to wild-type influenza was significantly increased or decreased in LAIV recipients relative to control groups in any comparison.
All medically attended events
To analyze the many rate comparisons for individual MAEs that occurred at a significantly higher or lower rate among LAIV recipients within the varied aged groups, settings, time intervals and dose number, graphic representations were constructed. The statistically significant differences are represented in 2-dimensional "heat map" graphics, similar to those commonly used to display ). Events occurring at a significantly higher rate after live attenuated influenza vaccine (LAIV) are coded orange and those occurring at a significantly lower rate after LAIV are coded in blue. The within-cohort analysis (self-control) columns are fewer in number because this analysis was performed within the 21-day postvaccination interval only. The majority of significant events occurred in the clinic setting after dose 1. Most events occurring at a higher rate after LAIV (orange) are found within the unvaccinated comparison group columns whereas most events that occurred at a lower rate after LAIV (blue) are found within the TIV-vaccinated comparison group columns. Events counted as part of the prespecified diagnoses of interest and those occurring within 3 and 180 days of vaccination are not included in the figure. Events listed are those which were significant prior to the adjustment for multiple comparisons. up-and downregulation of various associated gene segments [10] ( Figs. 1 and 2) . Of the 9496 incidence rate comparisons performed, a total of 372 (4%) yielded statistically significant differences: 204 incidence rates were higher and 168 incidence rates were lower in LAIV recipients in comparison with any of the 3 control groups in various settings and within various time frames postvaccination. Of the 372 rate comparisons, 307 were from individual MAE terms and 65 were from PSDIs. Of the 65 significant comparisons from the PSDI collected across all settings 45 came from individual diagnoses; these differences were also identified as elevated MAEs in the clinic setting ( Figs. 1 and 2) . The remaining 20 PSDI comparisons resulted from analyses of any acute respiratory tract, acute gastrointestinal tract, or asthma and wheezing events ( Table 3) . By control group, 155 (76%) of the rate comparisons that were increased after LAIV were in relationship to unvaccinated controls, and 126 (75%) of the rate comparisons that were decreased after LAIV were in relationship to TIV-vaccinated controls.
The majority of significant individual MAEs occurred in the clinic setting (96%), only 3% and 1% occurred in the ED and hospital settings, respectively. Only 1 MAE rate comparison was associated with a significant increase among LAIV recipients relative to all 3 control groups. There were 7 events of breast lump/cyst in LAIV recipients 9-17 years of age in the clinic setting through 21 days postvaccination and no events in the TIV-vaccinated, unvaccinated and within-cohort controls. Five of these events were preexisting, and 1 event appeared to be gynecomastia in an adolescent male. Respiratory events were found to occur at a lower rate among LAIV recipients in comparison with TIV-vaccinated controls. In both age groups, medically attended events related to psychiatric disorders overall and specifically for attention deficit disorder/attention deficit hyperactivity disorder (ADD/ADHD), depression and behavioral disorders were found to occur at an increased rate in LAIV recipients compared with TIV recipients and those unvaccinated. Upon review of subjects with psychiatric disorders, approximately 70% had evidence of prior healthcare visits for similar diagnoses within the Kaiser Permanente database; overall and for specific diagnoses, the proportion with evidence of prior visits was similar for LAIV and controls. A temporal analysis of these conditions showed no evidence of clustering of events within the 42 days postvaccination.
Asthma and wheezing events were evaluated in detail. There were a total of 17 statistically significant rate comparisons in the asthma and wheezing PSDI analysis; all events occurred at lower rates in LAIV recipients relative to controls. For asthma and wheezing events captured under the PSDI category of acute respiratory tract events, 7 rate comparisons of asthma/RAD events and 3 rate comparisons of wheezing/SOB events were significantly decreased in LAIV recipients relative to controls. For asthma and wheezing events analyzed by individual MAEs, asthma events occurred at a lower rate in LAIV recipients relative to controls in 7 rate comparisons in the clinic setting and 1 rate comparison in the ED setting. Exercise-induced asthma events occurred at lower rates in LAIV recipients relative to controls in 2 rate comparisons in the clinic setting, and wheezing events occurred at lower rates in LAIV recipients relative to controls in 3 rate comparisons in the clinic setting. All but 1 of these rate comparisons occurred in comparison with those vaccinated with TIV. There were no asthma/wheezing events that occurred at a higher rate in LAIV recipients relative to controls in any of the above analyses (see Supplemental Digital Content 2, columns are fewer in number because this analysis was performed within the 21-day postvaccination interval only. The majority of significant events occurred in the clinic setting after dose 1. Most events occurring at a higher rate after LAIV (orange) are found within the unvaccinated comparison group columns whereas most events that occurred at a lower rate after LAIV (blue) are found within the TIV-vaccinated comparison group columns. Events counted as part of the prespecified diagnoses of interest and those occurring within 3 and 180 days of vaccination are not included in the figure. Events listed are those which were significant prior to the adjustment for multiple comparisons.
which shows hazard ratios of asthma and wheezing events after vaccination with LAIV versus comparators).
No anaphylaxis events occurred within the 3-day risk period postvaccination in either LAIV recipients or any control group. Within 3 days of LAIV vaccination there were 9 cases of urticaria (8 in the clinic setting and 1 in the ED setting). The rate of urticaria within 3 days of vaccination was not significantly increased or decreased in LAIV recipients relative to control groups in any comparison.
After the post hoc adjustment for multiple comparisons, 48 of the 372 incidence rate comparisons remained statistically significant (Tables 4 and 5 ). In children 5-8 years of age, events occurring at an increased rate after vaccination with LAIV were psychiatric conditions, vision disorders, and well care visits; all were relative to unvaccinated controls. Events occurring at a lower rate after vaccination with LAIV included any acute respiratory tract event, any asthma and wheezing event, asthma and asthma/RAD; all were relative to TIV-vaccinated controls. For children 9-17 years of age, events occurring at a higher rate after vaccination with LAIV included those associated with routine well/preventive care, psychiatric conditions, and trauma; all were relative to unvaccinated controls. Any event in the clinic setting was also increased relative to unvaccinated controls. Events occurring at a lower rate after vaccination with LAIV included any acute respiratory tract event, any asthma and wheezing event, addiction, asthma, dental conditions, postsurgical state/complication and pregnancy examination; all were relative to TIV-vaccinated controls. Pregnancy examination was also decreased relative to unvaccinated controls.
A total of 10 pregnancies were noted in LAIV recipients 14-17 years of age. Two subjects were vaccinated before their last menstrual period, 7 were vaccinated in the first trimester, and 1 was vaccinated in the second trimester. Of the 9 pregnancies with known outcomes, 6 had elective abortions, 1 had a spontaneous abortion, and 2 had live births. The 2 live births were both full-term infants with no noted adverse events or congenital anomalies.
Discussion
This study evaluated the rate of MAEs, SAEs, hospitalizations, and deaths after LAIV vaccination in patients 5-17 years of age compared with the rates in 3 different sets of controls, in a total of 131,854 children, representing the largest safety study of LAIV to date. SAEs within 42 days of vaccination were uncommon, and the most common diagnoses found (psychiatric conditions, appendicitis, and trauma) mirrored the most common causes for hospitalization in children younger than 15 years [11] . Only 2 SAEs were considered to be possibly related to the vaccine, and the subjects both had a history of the event or preexisting symptoms of the condition. Anaphylaxis after LAIV vaccination was not seen, and urticaria within 3 days of vaccination was uncommon. Similar to an analysis from the Vaccine Adverse Events Reporting System from the first 2 postlicensure years of LAIV, this study did not identify any unexpected serious risks when the vaccine was used in the approved population [12] .
Because of the exploratory nature of this study and the lack of formal hypothesis testing, no corrections were made for multiple comparisons in the prespecified analysis. As a result, owing to the large number of rate comparisons, one would expect many statistically significant results. Most of the events occurring at a higher rate after vaccination with LAIV were found in comparison with unvaccinated controls whereas most of the events occurring at a lower rate after vaccination with LAIV were found in comparison with TIV-vaccinated controls. These differences are most likely the result of underlying differences in the nonrandomized comparison groups that remained despite subject matching. Given the warning against use of LAIV in individuals with underlying medical conditions, it is likely that TIV-vaccinated controls had a poorer health status relative to LAIV-vaccinated controls, even after exclusion of individuals with identifiable high-risk underlying medical conditions from the analysis populations. This underlying bias is consistent with the findings of decreased rates of respiratory events among LAIV recipients relative to TIV-vaccinated controls that remained after adjusting for multiple comparisons.
It also appears likely that despite matching there were underlying differences between LAIV recipients and unvaccinated controls, with unvaccinated controls being less likely to access vaccination and healthcare in general. This could explain the increased rate of events related to routine preventive care in LAIV recipients compared with those unvaccinated, such as well visits, vision disorder (a combination of codes including myopia, hyperopia, and other routine visual disorders), acne, obesity, nail disorder, and congenital anomaly (given the age of our study population this code represented pre-existing congenital anomalies, not those in the offspring of a study subject).
A selection bias for or against LAIV in individuals with certain medical conditions could result in an apparent increased or decreased rate of the condition in LAIV recipients compared with controls. This phenomenon explains the decreased rates of pregnancy-related events among LAIV recipients; there is a warning against the use of LAIV in pregnant women. Similarly, the increased rates of some psychiatric and behavioral disorders such as attention deficit disorder/attention deficit hyperactivity disorder and depression among LAIV recipients 9-17 years of age appear to be the result of individuals with those conditions selecting LAIV because of its intranasal administration or its lack of thimerosal and other preservatives. This selection bias has been observed in analyses of children receiving LAIV versus TIV in a large, national private insurance claims database, MarketScan ® Research Data (Thomson Reuters, New York, NY, USA). Other notable findings were those related to influenza. The lower rates of influenza in children 5-8 years of age within 42 days of vaccination compared with those unvaccinated or vaccinated with TIV are likely a result of the efficacy of LAIV and high rate of medically attended influenza illness in this age group. Among those 9-17 years of age, there was an increase in influenza within 21 days of vaccination in the withincohort analysis. This could be due to lower vaccine efficacy in the period immediately following vaccination, while protective immune responses are still developing, or due to exposure to wildtype influenza at the time of vaccination. Additionally, it could be due to individuals with other respiratory illnesses being diagnosed with influenza owing to detection of LAIV vaccine strains by point-of-care testing. Although no reduction in influenza related hospitalizations was seen among those vaccinated with LAIV compared with unvaccinated subjects, the study was not designed or powered to detect such a difference, most notably because hospitalizations suspected to be caused by influenza were not systematically tested or identified. Despite the underlying differences in LAIV-vaccinated, TIVvaccinated, and unvaccinated populations, the inclusion of TIV-vaccinated and unvaccinated control groups in the study design was valuable to enhance the ability to interpret the study data. If there had been a large, true increased risk of a specific event among LAIV recipients, it would have been detectable in comparison with TIV-vaccinated controls despite the underlying differences in the study populations. Similarly, the lack of an increase relative to unvaccinated controls despite the underlying bias provides evidence that an event is likely not increased in LAIV recipients. However, given the underlying biases for the comparisons to TIV-vaccinated and unvaccinated controls, the single most valuable comparison appears to be the self-control analysis as it controls for many of the covariates that are uncontrolled in analyses comparing disparate groups. It is reassuring that very few events were detected at an increased rate after LAIV vaccination in the self-control analysis, that those detected were generally due to minor illness, and that no statistically significant differences in the self-control analyses remained after adjusting for multiple comparisons.
Because previous studies demonstrated that LAIV was associated with an increase in medically attended wheezing events in young children [3, 4] , a comprehensive analysis of wheezing and asthma events was conducted. Events of asthma and wheezing were found to be decreased after vaccination with LAIV in all settings combined, the clinic setting, and the ED setting; within 21, 42, and 180 days of vaccination; in both age groups; after dose 1 and dose 2; and in comparison to all 3 control groups. There were no increased rates of events of asthma and wheezing after LAIV in any rate comparisons. As described above, differences in the health status of the 2 populations likely explain the reduced rates of events within the LAIV-vaccinated versus TIV-vaccinated populations. However, it is reassuring that the rate of wheezing and asthma was not increased in any comparisons, particularly those compared with unvaccinated subjects and the self-control analysis.
Strengths of the current study include the large sample size, the ability to examine all MAEs for any diagnosis, and the ability to capture events after the real-world use of LAIV over multiple influenza seasons. However, as discussed above, the nonrandomized design of the study is likely responsible for many of the observed differences between comparison groups. Furthermore, this study design did not allow for the systematic determination of whether an event observed after vaccination was the result of a pre-existing condition; evaluations of prior medical history were only feasible for select subjects through detailed chart review. Finally, it is important to note that inferences drawn from the evaluated KP members may not be completely generalizable to the overall US population.
Conclusion
In summary, in this study of more than 40,000 LAIV recipients 5-17 years of age, rates of MAEs and SAEs were compared between LAIV-vaccinated individuals and multiple nonrandomized controls. SAEs and hospitalizations after vaccination with LAIV were uncommon, and no pattern of MAEs was found to occur at higher rates than control groups. The results of this study are consistent with preapproval studies [3, 13, 14] and with reports to the Vaccine Adverse Events Reporting System in the years after the initial approval of LAIV [12] , which demonstrated no significant adverse outcomes after receipt of LAIV by eligible individuals 5-17 years of age. A similar study is currently underway in children 2-4 years of age.
